News

In COVID-19 news, an advisory committee recommends approval of oral antiviral after Merck releases updated data. The FDA made three approvals this week: an imaging agent to detect ovarian cancer and a vaccine for hepatitis B, and Darzalex Faspro is given an additional indication. New regulatory applications include: Lynparza for early breast cancer; the psoriasis therapy deucravacitinib, a pneumococcal vaccine for children, and an anemia therapy. The regulatory agency also paused the updated clozapine REMS program.

Merck now says molnupiravir reduces the risk of hospitalization or death from COVID-19 by 30% after all data have been analyzed. Previously, an interim analysis showed a 50% reduction in hospitalization or death.

Briana Contreras, associate editor of Managed Healthcare Executive spoke with WellRight CEO, Neepa Patel, on the topic of wellness programs in healthcare and the need for employers and health plans to roll out new, effective, holistic and innovative programs for patients. Patel did discuss the challenges that some organization can face when rolling out these programs, but she explained how accessible, affordable and beneficial these programs are for patients mental health and wellbeing.